Jonathan Young sold $573K of Akero Therapeutics (AKRO)

Executed Sep 2 2025, disclosed Sep 4 2025, 2 days later.

Value, as filed

$573K

12,439 sh across 2 lots

Executed

Sep 2 2025

the trade date, as filed

Disclosed

Sep 4 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

JY Jonathan Young Chief Operating Officer profile →

Jonathan Young (Chief Operating Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in AKRO. The largest single filing was $597K of AKRO (12,500 sh across 2 lots, as filed), executed Oct 1 2025.

The name

AKRO AKRO AKRO · 63 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Jonathan Young in AKRO

AKROSALE Akero Therapeutics, Inc. $597K
12,500 sh across 2 lots
Exec Oct 1 2025
Filed Oct 3 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $532K
11,151 sh × $47.72
Exec Aug 12 2025
Filed Aug 13 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $135K
2,493 sh × $53.99
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $2.2M
50,000 sh across 2 lots
Exec Mar 4 2025
Filed Mar 5 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $538K
10,000 sh across 2 lots
Exec Feb 3 2025
Filed Feb 5 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $280K
10,000 sh × $28.03
Exec Jan 2 2025
Filed Jan 6 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $321K
10,000 sh × $32.13
Exec Dec 2 2024
Filed Dec 4 2024 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. $1.6M
50,424 sh across 2 lots
Exec Nov 1 2024
Filed Nov 5 2024 · 5:30 PM ET